Xylem Statistics
Total Valuation
Xylem has a market cap or net worth of $34.32 billion. The enterprise value is $35.27 billion.
| Market Cap | 34.32B |
| Enterprise Value | 35.27B |
Important Dates
The next estimated earnings date is Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Aug 28, 2025 |
Share Statistics
Xylem has 243.41 million shares outstanding. The number of shares has increased by 0.39% in one year.
| Current Share Class | 243.41M |
| Shares Outstanding | 243.41M |
| Shares Change (YoY) | +0.39% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 93.57% |
| Float | 241.76M |
Valuation Ratios
The trailing PE ratio is 36.72 and the forward PE ratio is 27.68. Xylem's PEG ratio is 2.31.
| PE Ratio | 36.72 |
| Forward PE | 27.68 |
| PS Ratio | 3.93 |
| Forward PS | 3.71 |
| PB Ratio | 3.10 |
| P/TBV Ratio | 71.05 |
| P/FCF Ratio | 40.66 |
| P/OCF Ratio | 28.04 |
| PEG Ratio | 2.31 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.79, with an EV/FCF ratio of 41.79.
| EV / Earnings | 37.60 |
| EV / Sales | 4.04 |
| EV / EBITDA | 19.79 |
| EV / EBIT | 29.17 |
| EV / FCF | 41.79 |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.90 |
| Quick Ratio | 1.31 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 1.10 |
| Debt / FCF | 2.52 |
| Interest Coverage | 33.58 |
Financial Efficiency
Return on equity (ROE) is 8.63% and return on invested capital (ROIC) is 5.84%.
| Return on Equity (ROE) | 8.63% |
| Return on Assets (ROA) | 4.59% |
| Return on Invested Capital (ROIC) | 5.84% |
| Return on Capital Employed (ROCE) | 8.12% |
| Revenue Per Employee | $379,565 |
| Profits Per Employee | $40,783 |
| Employee Count | 23,000 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 5.10 |
Taxes
In the past 12 months, Xylem has paid $226.00 million in taxes.
| Income Tax | 226.00M |
| Effective Tax Rate | 19.48% |
Stock Price Statistics
The stock price has increased by +6.18% in the last 52 weeks. The beta is 1.09, so Xylem's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +6.18% |
| 50-Day Moving Average | 138.59 |
| 200-Day Moving Average | 126.69 |
| Relative Strength Index (RSI) | 51.88 |
| Average Volume (20 Days) | 1,170,724 |
Short Selling Information
The latest short interest is 2.29 million, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 2.29M |
| Short Previous Month | 2.29M |
| Short % of Shares Out | 0.94% |
| Short % of Float | 0.95% |
| Short Ratio (days to cover) | 1.87 |
Income Statement
In the last 12 months, Xylem had revenue of $8.73 billion and earned $938.00 million in profits. Earnings per share was $3.84.
| Revenue | 8.73B |
| Gross Profit | 3.30B |
| Operating Income | 1.21B |
| Pretax Income | n/a |
| Net Income | 938.00M |
| EBITDA | 1.78B |
| EBIT | 1.21B |
| Earnings Per Share (EPS) | $3.84 |
Balance Sheet
The company has $1.17 billion in cash and $2.12 billion in debt, giving a net cash position of -$954.00 million or -$3.92 per share.
| Cash & Cash Equivalents | 1.17B |
| Total Debt | 2.12B |
| Net Cash | -954.00M |
| Net Cash Per Share | -$3.92 |
| Equity (Book Value) | 11.31B |
| Book Value Per Share | 45.50 |
| Working Capital | 2.07B |
Cash Flow
In the last 12 months, operating cash flow was $1.22 billion and capital expenditures -$380.00 million, giving a free cash flow of $844.00 million.
| Operating Cash Flow | 1.22B |
| Capital Expenditures | -380.00M |
| Free Cash Flow | 844.00M |
| FCF Per Share | $3.47 |
Margins
Gross margin is 37.81%, with operating and profit margins of 13.85% and 10.74%.
| Gross Margin | 37.81% |
| Operating Margin | 13.85% |
| Pretax Margin | 13.29% |
| Profit Margin | 10.74% |
| EBITDA Margin | 20.41% |
| EBIT Margin | 13.85% |
| FCF Margin | 9.67% |
Dividends & Yields
This stock pays an annual dividend of $1.60, which amounts to a dividend yield of 1.14%.
| Dividend Per Share | $1.60 |
| Dividend Yield | 1.14% |
| Dividend Growth (YoY) | 10.64% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 40.63% |
| Buyback Yield | -0.39% |
| Shareholder Yield | 0.74% |
| Earnings Yield | 2.73% |
| FCF Yield | 2.46% |
Analyst Forecast
The average price target for Xylem is $150.75, which is 6.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $150.75 |
| Price Target Difference | 6.92% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 5.59% |
| EPS Growth Forecast (5Y) | 14.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Xylem has an Altman Z-Score of 4.29 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.29 |
| Piotroski F-Score | 8 |